Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... , July 1, 2015 InferMed ... technology will ... evidence-based clinical s olutions suite   ... and medical information products and services, announced today the acquisition ... decision support (CDS) technology company. InferMed,s Arezzo technology ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... All amounts are in U.S. dollars, QUEBEC ... AEZS; TSX: AEZ;), a global biopharmaceutical company focused ... completed the sale,of its Quebec City property for ... AEterna Zentaris also entered into a long-term lease ...
... 27 /Xinhua-PRNewswire-FirstCall/ -- China Clean,Energy Inc. (OTC ... a leading producer of environmentally-friendly specialty,chemical products ... Republic of,China, today announced that it continues ... its specialty chemical products and that it,continues ...
... New spray-on films developed by UC San Diego chemists ... quickly reveal trace amounts of nitrogen-based explosives. , Contaminated ... blue under ultraviolet light. One of the films can ... that could provide evidence to help solve a crime, ...
Cached Biology Technology:AEterna Zentaris Sells Quebec City Building for $7.1 million 2China Clean Energy Updates Business Outlook 2China Clean Energy Updates Business Outlook 3Glowing films developed by UC San Diego chemists reveal traces of explosives 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... chemicals may one day be synthesised using biotechnology, following ... provide soldier beetles with their potent predator defence system., ... published details of the gene identification breakthrough and potential ... ., "For the first time, our team has been ...
... A study conducted by scientists at the Royal Botanic Gardens, ... climate change alone could lead to the extinction of wild ... of this century. Wild Arabica is considered important ... considerable genetic diversity. The Arabicas grown in the world,s coffee ...
... causes lung-damaging inflammation in cystic fibrosis (CF), and that ... finding offers a potential new drug target for treating ... illness and death for people with CF. "Developing ... big step forward," says Dr. Stuart Turvey, who led ...
Cached Biology News:Gene find turns soldier beetle defence into biotech opportunity 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 3New study suggests that Arabica coffee could be extinct in the wild within 70 years 4New study suggests that Arabica coffee could be extinct in the wild within 70 years 5New drug target found for cystic fibrosis lung disease 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White ... INERT GAS. A cell-permeable, reversible inhibitor of ... x-40 (ED 50 = 2.6 ... = 2.7 μM) in HEK293 cells ...
cystatin A (N-18)...
...
Biology Products: